Description
Cytosine base editors (CBEs) system is constructed by fusing an artificially evolved cytosine deaminase to a mutated Cas9 that is a single-strand DNA nickase, can precisely and permanently convert C·G to T·A with the guidance of a target-specific guide RNA (gRNA) without creating a double-strand DNA break and without requiring an exogenous DNA repair donor. This mRNA is human codon optimized CBE4max SpCas9 variant named SpG, with sequence originally from Walton et al Science 2020 Apr 17; 368(6488):290-296.
This mRNA features:
- A Cap 1 structure with high capping efficiency
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response
- GenScript’s patented UTR to enhance translation
- A 100A poly(A) tail to mimic natural mature mRNA |
| Form |
Liquid |
| Concentration |
1mg/mL |
| Full mRNA length |
5831nt |
| Full mRNA Molecular Weight |
1899231 |
| Storage buffer |
1mM Sodium citrate, pH6.5 |
| Storage condition |
Store at -20°C for short term (<3 months), store at -80°C for long term. |
| Appearance |
Clear and free of foreign particles |
| RNA Length |
Expected size band detected |
| RNA Content |
Target ± 5% |
| Integrity |
≥ 75% |
| OD260/OD280 |
1.70 ~ 2.30 |
| Capping Efficiency |
≥ 90% |
| Endotoxin |
< 10 EU/mg |
| pH |
Target ± 0.5 |
|
Transfect a total of 0.5-1.5 µg of CBEmax mRNA and sgRNA per well (recommended molar ratio 1:10), using a transfection reagent, electroporation, or LNP encapsulation in a 24-well plate (~2 × 10⁵ cells/well). Assess genome editing efficiency 48-72 hours post-transfection via sequencing. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
